Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 18/20 | 0.45 |
| ▸ | ACACA | Q13085 | 13/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495968 | 0.82 | USP2 (0.43) | ACACBACACA | |
| SCHEMBL3495906 | 0.82 | ACACB (0.64) | ACACBACACA | |
| SCHEMBL9963146 | 0.74 | ACACB (0.39) | ACACBACACA | |
| SCHEMBL19036979 | 0.73 | ACACB (0.35) | ACACBACACAPOLBGAA | |
| SCHEMBL15516069 | 0.70 | ALDH1A1 (0.44) | POLBGAA | |
| SCHEMBL3498783 | 0.69 | USP2 (0.39) | ACACBACACA | |
| SCHEMBL18132145 | 0.69 | OTUD7B (0.40) | ACACBACACA | |
| SCHEMBL17611720 | 0.69 | OTUD7B (0.46) | ACACBACACA | |
| Trifluoroacetic Acid SCHEMBL3498589 | 0.69 | ACACB (0.51) | ACACBACACAADRB2ADRB3KCNH2 | |
| SCHEMBL4722776 | 0.68 | ACACB (0.53) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ACACB 6/4885ACACA 1/4885POLB 3928/4885 |
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | ACACB 3/4885ACACA 1/4885POLB 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.